Monitoring angiotensin receptor-neprilysin inhibitor usage and clinical outcomes in heart failure patients: Real-world evidence from a tertiary care center in Thailand
Article Sidebar
Main Article Content
Abstract
This retrospective study investigated the real-world usage patterns, effectiveness, and safety of the angiotensin receptor–neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) at a tertiary care center in Thailand. A total of 249 patients who initiated ARNI between January 1, 2018, and June 30, 2022, were included. The average age was 61.3 ± 11.1 years, and 69.1% were male. The mean BMI was 25.7 ± 13.4 kg/m², and the average body weight was 66.4 ± 13.8 kg. The baseline left ventricular ejection fraction (LVEF) was 28.4% ± 8.7%. Most patients (57.4%) were administered ARNI at a dose of 100 mg/day. The average follow-up was 18.5 months, and the maximum tolerable dose was 179.0 ± 98.7 mg/day, with 12.0% attaining the target dose. No deaths were recorded; however, 8.8% of the patients were hospitalized for heart failure. LVEF improved significantly at 6, 12, 18, 24, and 30 months, with 67.2% achieving LVEF ≥40%. Discontinuation of ARNI occurred in 20.9%, primarily due to hyperkalemia (9.3%), hypotension (6.0%), and a decrease in renal function (5.2%). These findings confirm ARNI’s effectiveness in improving cardiac function in Thai HFrEF patients while emphasizing the need for close monitoring to manage adverse effects and optimizing dosing strategies.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Atallah, B., Sadik, Z. G., Hisham, M., Kalagieh, O., Hamour, I., Gabra, G., El Banna, M., Soliman, M., Cherfan, A., & Bader, F. (2019). A per-protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the middle east gulf region. ESC Heart Fail, 6(4), 758−763. https://doi.org/10.1002/ehf2.12452
Chang, H. Y., Chen, K. C., Fong, M. C., Feng, A. N., Fu, H. N., Huang, K. C., Chong, E., & Yin, W. H. (2020a). Recovery of left ventricular dysfunction after Sacubitril/Valsartan: Predictors and management. Journal of Cardiology, 75(3), 233−241. https://doi.org/10.1016/j.jjcc.2019.08.005
Chang, H. Y., Feng, A. N., Fong, M. C., Hsueh, C. W., Lai, W. T., Huang, K. C., Chong, E., Chen, C. N., Chang, H. C., & Yin, W. H. (2019). Sacubitril/Valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. Journal of Cardiology, 74(4), 372−380. https://doi.org/10.1016/j.jjcc.2019.03.010
Chang, P. C., Wang, C. L., Hsiao, F. C., Wen, M. S., Huang, C. Y., Chou, C. C., & Chu, P. H. (2020b). Sacubitril/Valsartan vs. Angiotensin receptor inhibition in heart failure: A real-world study in Taiwan. ESC Heart Fail, 7(5), 3003−3012. https://doi.org/10.1002/ehf2.12924
Cheang, I., Shi, S., Lu, X., Liao, S., Zhu, X., Su, X., Lu, Q., Yuan, J., Xu, D., Zhang, M., Dai, C., Wang, J., Yuan, F., Zhao, Y., Zhou, J., & Li, X. (2022). Efficacy and dosage pattern of Sacubitril/Valsartan in Chinese heart failure with reduced ejection fraction patients. Journal of Cardiovascular Translational Research, 15(5), 1192−1202. https://doi.org/10.1007/s12265-022-10236-x
Chng, B. L. K., Hon, J. S., Chan, H., Zheng, Y., Gao, F., Teo, L. Y. L., & Sim, K. L. D. (2021). Safety and tolerability of Sacubitril/Valsartan initiation in inpatient versus outpatient setting: A retrospective real world study. Heart, Lung and Circulation, 30(5), 674−682. https://doi.org/10.1016/j.hlc.2020.08.014
Cho, D. H., Choi, J., Youn, J. C., Kim, M. N., Lee, C. J., Son, J. W., & Yoo, B. S. (2025). Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction. ESC Heart Fail, 12(1), 603−612. https://doi.org/10.1002/ehf2.15117
Damman, K., Gori, M., Claggett, B., Jhund, P. S., Senni, M., Lefkowitz, M. P., Prescott, M. F., Shi, V. C., Rouleau, J. L., Swedberg, K., Zile, M. R., Packer, M., Desai, A. S., Solomon, S. D., & McMurray, J. J. V. (2018). Renal effects and associated outcomes during Angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail, 6(6), 489−498. https://doi.org/10.1016/j.jchf.2018.02.004
Giovinazzo, S., Carmisciano, L., Toma, M., Benenati, S., Tomasoni, D., Sormani, M. P., Porto, I., Canepa, M., Senni, M., Metra, M., & Ameri, P. (2021). Sacubitril/Valsartan in real-life European patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis. ESC Heart Fail, 8(5), 3547−3556. https://doi.org/10.1002/ehf2.13547
Hsiao, F. C., Lin, C. P., Yu, C. C., Tung, Y. C., & Chu, P. H. (2022). Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: A retrospective multi-institutional study. Frontiers in Cardiovascular Medicine, 9, Article 794707. https://doi.org/10.3389/fcvm.2022.794707
Hsiao, F. C., Wang, C. L., Chang, P. C., Lu, Y. Y., Huang, C. Y., & Chu, P. H. (2020). Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Taiwan. Journal of Cardiovascular Pharmacology and Therapeutics, 25(2), 152−157. https://doi.org/10.1177/1074248419872958
Maddox, T. M., Januzzi, J. L., Jr., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., Motiwala, S. R., Oliveros, E., Walsh, M. N., Wasserman, A., Yancy, C. W., & Youmans, Q. R. (2024). 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: A report of the American college of cardiology solution set oversight committee. Journal of the American College of Cardiology, 83(15), 1444−1488. https://doi.org/10.1016/j.jacc.2023.12.024
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Bohm, M., Burri, H., Butler, J., Celutkiene, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., . . . Group, E. S. C. S. D. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599−3726. https://doi.org/10.1093/eurheartj/ehab368
McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., Investigators, P.-H., & Committees. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993−1004. https://doi.org/10.1056/NEJMoa1409077
Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M. S., Cho, H. J., Choi, J. O., Lee, H. Y., Hwang, K. K., Kim, K. H., Yoo, B. S., Choi, D. J., Baek, S. H., Jeon, E. S., Kim, J. J., Cho, M. C., Chae, S. C., Oh, B. H., & Kang, S. M. (2019). Real-world eligibility for Sacubitril/Valsartan in heart failure with reduced ejection fraction patients in Korea: Data from the Korean acute heart failure (KorAHF) registry. International Journal of Heart Failure, 1(1), 57−68. https://doi.org/10.36628/ijhf.2019.0007
Rattanavipanon, W., Sotananusak, T., Yamaae, F., Chandrsawang, A., Kaewkan, P., Nathisuwan, S., & Yingchoncharoen, T. (2021). Real-world experience of Angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: A single-center, retrospective analysis. BMC Cardiovasc Disord, 21(1), 324. https://doi.org/10.1186/s12872-021-02145-9
Yang, I. N., Huang, C. Y., Yang, C. T., Toh, H. S., Chang, W. T., Su, L. W., Lin, Y. M., Wang, M. C., Wang, H. Y., & Liao, C. T. (2024). Real-world experience of Angiotensin receptor-neprilysin inhibitors in patients with heart failure and dialysis. Frontiers in Cardiovascular Medicine, 11, Article 1393440. https://doi.org/10.3389/fcvm.2024.1393440
